Comments on "dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer".
作者信息
Wang Shan-Ying, Shiau Yu-Chien, Hsu Chen-Xiong
机构信息
Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
出版信息
Thorac Cancer. 2022 Dec;13(24):3513-3514. doi: 10.1111/1759-7714.14710. Epub 2022 Oct 26.
Abstract
摘要
相似文献
1
Comments on "dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer".
Thorac Cancer. 2022 Dec;13(24):3513-3514. doi: 10.1111/1759-7714.14710. Epub 2022 Oct 26.
2
Dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.
Thorac Cancer. 2022 Sep;13(17):2524-2531. doi: 10.1111/1759-7714.14562. Epub 2022 Jul 12.
3
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886.
4
Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Q J Nucl Med Mol Imaging. 2021 Jun;65(2):172-177. doi: 10.23736/S1824-4785.19.03146-7. Epub 2019 Mar 25.
5
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Clin Lung Cancer. 2020 Jan;21(1):28-36. doi: 10.1016/j.cllc.2019.07.004. Epub 2019 Jul 22.
6
18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
J Nucl Med. 2016 Jun;57(6):849-54. doi: 10.2967/jnumed.115.167684. Epub 2016 Jan 28.
7
Comprehensive F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study.
Front Immunol. 2022 Nov 17;13:994917. doi: 10.3389/fimmu.2022.994917. eCollection 2022.
8
The utility of F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17.
9
New insight on the correlation of metabolic status on F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1127-1136. doi: 10.1007/s00259-019-04500-7. Epub 2019 Sep 9.
10
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.
引用本文的文献
1
The utility of F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer.
Cancer Imaging. 2024 Sep 10;24(1):120. doi: 10.1186/s40644-024-00772-x.
本文引用的文献
1
Integrating F-FDG PET/CT with lung dose-volume for assessing lung inflammatory changes after arc-based radiotherapy for esophageal cancer: A pilot study.
Thorac Cancer. 2022 Nov;13(22):3114-3123. doi: 10.1111/1759-7714.14661. Epub 2022 Sep 26.
2
Dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.
Thorac Cancer. 2022 Sep;13(17):2524-2531. doi: 10.1111/1759-7714.14562. Epub 2022 Jul 12.
3
PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients.
Diagnostics (Basel). 2021 Jan 30;11(2):210. doi: 10.3390/diagnostics11020210.
4
Imaging for Response Assessment in Cancer Clinical Trials.
Semin Nucl Med. 2020 Nov;50(6):488-504. doi: 10.1053/j.semnuclmed.2020.05.001. Epub 2020 Jun 10.
5
New insight on the correlation of metabolic status on F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1127-1136. doi: 10.1007/s00259-019-04500-7. Epub 2019 Sep 9.
6
Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic F Fluorodeoxyglucose PET.
Radiology. 2017 May;283(2):547-559. doi: 10.1148/radiol.2016160329. Epub 2016 Nov 15.
7
Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):960-6. doi: 10.1016/j.ijrobp.2010.10.064. Epub 2011 Mar 26.
Zotero 插件